AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03000790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lingual Ring Splint
Description: A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior archwill make the Ring around the tongue
Study NCT00441922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 38 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
Study NCT00441922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine at the dose of 25 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
Study NCT02579772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.
Study NCT02579772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.
Study NCT04652661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 30 children will be sedated with 2 μg/kg intranasal DEX.
Study NCT04652661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 30 children will be sedated with 0.3 mg/kg intranasal midazolam.
Study NCT04788342 — intervention group
Intervention type: DEVICE
Intervention: pulse wave recording, echocardiography.
Description: pulse wave recording using a single-channel electrocardiogram cardiomonitor with photoplethysmography, conducting echocardiography according to a standard protocol with the determination of systolic function of the left ventricle
Study NCT02643147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA125 guided strategy
Description: Initial dose of intravenous furosemide ≤80 mg / day regardless of prior dose of loop diuretics who were receiving.
Study NCT02643147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA125 guided strategy
Description: Initial dose of intravenous furosemide ≥120 mg/day or 2.5 times the dose the patient was taking at home.
Study NCT02643147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Strategy
Description: The dosage of loop diuretics is done according to the presence of symptoms and signs of systemic congestion and current recommendations
Study NCT03007797 — intervention group
Intervention type: BEHAVIORAL
Intervention: vaccination rate for influenza
Study NCT03169998 — intervention group
Intervention type: DEVICE
Intervention: EV1000 platform
Description: a continuous arterial pressure monitoring was performed via EV1000/ FloTrac (Edwards Lifesciences, Irvine, CA, USA) (Fig 1) with the continuous monitoring of cardiac index (CI), stroke volume index (SVI) and stroke volume (SV).
Study NCT04001335 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dental Broach
Description: Dental broach, RDT and PCR
Study NCT00486252 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: This is a non-interventional study. Subgroups of naïve patients and patients with previous failure to beta-blockers therapy were analyzed.
Study NCT04074330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion.
Study NCT02645123 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Enraf-Nonius Sonopuls 692
Study NCT02645123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal mobilization
Description: passive physiological intervertebral movements and passive accessory posteroanterior mobilization
Study NCT02645123 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: swedish type massage
Description: petrissage, effleurage, tapotement
Study NCT02829385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and XELOX combined treatment group
Description: Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs.
Study NCT04626661 — intervention group
Intervention type: DEVICE
Intervention: COMET measurement system
Description: Photonics Healthcare B.V. has developed an innovative non-invasive bedside monitoring system to measure Cellular Oxygen METabolism (the COMET).The COMET's non-invasive cutaneous mitoPO2 measurements rely on the protoporphyrin IX-triple state lifetime technique (PpIX-TSLT). This technique measures oxygen by oxygen-dependent quenching of delayed fluorescence lifetime of 5-aminolevulinic acid-induced mitochondrial PpIX (protoporphyrin IX). PpIX is the final precursor of haem in the haem biosynthesis pathway and is synthetized in the mitochondria. Administration of exogenous 5-aminolevulinic acid enhances PpIX to detectable levels and enhances mitochondrial origin of the delayed fluorescence signal. Measurements are based on the detection of time of extinction of red light emitted by the tissue following excitation with green light. The technique has been tested and calibrated for use in isolated organs and in vivo.
Study NCT02188524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Tai Chi and Compensatory Stepping
Study NCT02645123 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: static hamstring stretch
Description: static hamstring stretching
Study NCT02645123 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham treatment
Description: touching of the skin overlying the lumbar area
Study NCT02314351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10 mg
Description: Intravenous form of metoclopramide is in the same appearance with placebo
Study NCT02314351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide 10 mg
Description: Intravenous form of metoclopramide is in the same appearance with placebo
Study NCT02314351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intravenous form of metoclopramide is in the same appearance with placebo
Study NCT02314351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous form of metoclopramide is in the same appearance with placebo
Study NCT02314351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute
Study NCT02314351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute
Study NCT00203034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasagiline mesylate
Description: 0.5 mg rasagiline mesylate oral once daily
Study NCT00203034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 mg rasagiline mesylate
Description: 1.0 mg rasagiline mesylate oral once daily
Study NCT00203034 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo once daily
Study NCT02559310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lefamulin
Description: antibacterial agent
Study NCT02559310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: antibacterial agent
Study NCT02559310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: antibacterial agent
Study NCT01376154 — intervention group
Intervention type: DRUG
Intervention: Lamivudine
Study NCT04463680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin 600 MG
Description: Administered daily for 2 weeks
Study NCT02536742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg, orally, daily for 3 weeks followed by 1 week off; repeated at every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
Study NCT02536742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg, intramuscularly on days 1 and 15 of cycle 1, then on day 1 (+/- 3 days) of every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
Study NCT03298269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement
Description: Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention led by a therapist that combines training in mindfulness, cognitive reappraisal, and savoring skills.
Study NCT03298269 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling
Description: A support group led by a therapist will allow participants to express emotions, share experiences, and receive social support.
Study NCT03753243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
Study NCT03753243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Patients will receive daily oral doses of study drug (enzalutamide 160 mg/day), which will be administered as four capsules/day to be taken at or near the same time each day.
Study NCT02605369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm: An integrated package
Description: See description in previous column
Study NCT00938405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl
Description: 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
Study NCT00938405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 3.75 gms/day in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
Study NCT01317329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinically prescribed CPAP therapy
Description: CPAP as prescribed by attending physician
Study NCT00134355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787
Study NCT04187859 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education Session
Description: Participants will receive an education session from their District Nurse, advising on how to improve their hydration.
Study NCT04187859 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prompting Cup
Description: The Droplet Cup is an electronic prompting cup that emits a sound and/or light to encourage the participant to take a drink
Study NCT03277352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose and schedule according to cohort and treatment group enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.
Study NCT03277352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat will be self-administered orally at the protocol-defined dose.
Study NCT03125850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: randomized to day ward
Description: Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
Study NCT03125850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: randomized to inpaitent
Description: Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
Study NCT00042653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 mg of placebo taken once daily orally 60 mg of placebo taken once daily orally 90 mg of placebo taken once daily orally 120 mg of placebo taken once daily orally 180 mg of placebo taken once daily orally
Study NCT00042653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 073
Description: 30 mg of AMG 073 taken once daily orally 60 mg of AMG 073 taken once daily orally 90 mg of AMG 073 taken once daily orally 120 mg of AMG 073 taken once daily orally 180 mg of AMG 073 taken once daily orally
Study NCT00076999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV oral solution
Description: Tipranavir oral solution
Study NCT00076999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV oral solution
Description: Ritonavir oral solution
Study NCT02708797 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic resonance imaging
Description: Patients and controls will first be studied with MRI. The total duration of MRI is about 60mn. These technic is not invasive.
Study NCT02708797 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transcranial Doppler
Description: Patients and controls will first be studied with TCD. The total duration of TCD is about 60mn. These technic is not invasive.
Study NCT02415231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: humor
Study NCT03438864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrotherapy, interferential current
Description: Interferential current, entry frequencies and beat frequencies were set differently in 2 groups, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
Study NCT03438864 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No current except for first 5 seconds, device open but does not appy electrotherapy.
Study NCT04949204 — intervention group
Intervention type: PROCEDURE
Intervention: Wearable sensor detection
Description: Empatica E4 wearable wrist sensor
Study NCT05861206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GT-MW group (5% Green tea), WT-MW group (5% White tea),EO-MW group (Listerine mouthrinse)
Description: Subsequently, each patient was instructed to use 15 mL of the mouthwash (5% Green tea, 5% White tea or Listerine mouthrinse) delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for a week. For the next 3 weeks, at the beginning of each week (8th, 15th and 22nd days), patients were invited to the clinic, oral hygiene instruction was repeated, and the mouthwashes to be used the following week were delivered to them.
Study NCT05861206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHX-MW group (0.12% CHX, as a positive control group)
Description: Subsequently, each patient was instructed to use 15 mL of the mouthwash (0.12% CHX) delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for a week. For the next 3 weeks, at the beginning of each week (8th, 15th and 22nd days), patients were invited to the clinic, oral hygiene instruction was repeated, and the mouthwashes to be used the following week were delivered to them.
Study NCT03277352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered IV at the protocol-defined dose.
Study NCT00707499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS747158
Description: Single dose administration.
Study NCT02284009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albiglutide weekly injection
Description: Albiglutide will be provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm region. The pen will deliver either 30 mg of albiglutide, 50 mg of albiglutide in a 0.5-mL injection volume. It may be administered at any time of day without regard to meals. It will be administered once a week on the same day each week
Study NCT02284009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo weekly injection
Description: Placebo provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a SC injection in the abdomen, thigh or upper arm region. It may be administered at any time of day, once a week on the same day each week, without regard to meals.
Study NCT02284009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Commercially available basal/bolus insulin regimen, self administered by the subject, in accordance to the prescription of the physician and as per the package insert
Study NCT02923505 — intervention group
Intervention type: PROCEDURE
Intervention: polygraphy or polysomnography
Study NCT03652350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-guided microwave ablation
Description: Using thermal ablation electrode ECO-100AL6 probe target the GGN zone with the guidance performed by CT (Bright Speed Scanner )
Study NCT01729715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet
Study NCT01729715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD
Study NCT03119883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-Carbon C 13-labeled Glutamine
Description: Given IV
Study NCT03119883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT03119883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of bone marrow aspirate samples
Study NCT03119883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uniformly-labeled [13C]glucose
Description: Given IV
Study NCT00390078 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-mBN32
Description: 3 immunizations: 1x 10E8_TCID50 MVA-mBN32
Study NCT00390078 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IMVAMUNE
Description: 3 immunizations: 1x 10E8_TCID50 IMVAMUNE
Study NCT04597970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cTACE-HAIC
Description: transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)
Study NCT00113815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 15 mg/kg/day
Study NCT00113815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 5 mg/kg/day
Study NCT00113815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 25 mg/kg/day
Study NCT00113815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study NCT01754415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hydraulic resistance circuit training
Description: 12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 10 types of equipments for different part of strength training.
Study NCT04608747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tahini
Description: Fifty grams of tahini were consumed by 20 healthy males
Study NCT02514200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topography-based CXL (KXL2)
Description: The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a topography-based arcuate shape with the Avedro KXL2® with an energy from 7.2-15.0 J/cm2 depending on the severity of the keratoconus.
Study NCT02192593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer CBT
Study NCT02514200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pulsed CXL (pCXL)
Description: The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a central round 8mm zone with the Avedro KXL2® with an energy of 5.4 J/cm2.
Study NCT02514200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated
Study NCT02514200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated
Study NCT02514200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Avedro KXL II
Description: The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.
Study NCT02514200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avedro KXL II
Description: The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.
Study NCT00865657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 3 mg Extended Release Tablets, single dose
Description: A: Experimental Subjects received Alpharma formulated products under non-fasting conditions